文献速递小儿麻醉疼痛医学

右美托咪定与扁桃体腺样体切除术患儿围术期阿片类药物消耗的关联

The Association of Dexmedetomidine on Perioperative Opioid Consumption in Children Undergoing Adenotonsillectomy With and Without Obstructive Sleep Apnea.
PubMed 文献 · Anesth Analg · 2021-01-01

该回顾性队列研究纳入941例在德克萨斯儿童医院接受扁桃体腺样体切除术的儿童,其中697例(74.1%)术中接受右美托咪定。多变量线性回归显示,术中右美托咪定每增加0.1 µg/kg,围术期总口服吗啡当量(OME)减少0.021 mg/kg(95% CI,-0.027至-0.015;P < .001),PACU停留时间增加1.14分钟(95% CI,0.30-1.99;P = .008)。合并阻塞性睡眠呼吸暂停(OSA)的患儿围术期阿片类药物消耗未见减少。

要点

  • 术中右美托咪定每增加0.1 µg/kg,围术期总OME降低0.021 mg/kg。
  • 右美托咪定使PACU停留时间小幅但显著延长1.14分钟。
  • OSA患儿未显示围术期阿片类药物消耗减少。

核心结论

  • 右美托咪定与扁桃体腺样体切除术患儿围术期总体阿片节俭效应相关,并使PACU停留时间小幅但统计学显著增加。
  • 合并OSA的患儿未表现出围术期阿片类药物消耗减少。

研究设计与样本

  • 暴露为术中右美托咪定,主要结局为围术期总阿片消耗(以口服吗啡当量OME计算),采用多变量线性回归估计关联。

主要发现

  • 术中右美托咪定每增加0.1 µg/kg,围术期总OME(mg/kg)减少0.021 mg/kg(95% CI,-0.027至-0.015;P < .001)。
  • 术中右美托咪定每增加0.1 µg/kg,PACU停留时间增加1.14分钟(95% CI,0.30-1.99;P = .008)。
  • 根据OSA存在与否,疼痛评分无显著差异。

临床怎么用

  • 对于接受扁桃体腺样体切除术的儿童,可考虑术中使用右美托咪定以减少围术期阿片类药物消耗。
  • 需注意右美托咪定可能延长PACU停留时间。
  • 对于合并OSA的患儿,右美托咪定的阿片节俭效应可能不明显,应个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexmedetomidine is used to reduce opioid consumption in pediatric anesthesia. However, there is conflicting evidence in pediatric adenotonsillectomy literature regarding the total perioperative opioid-sparing effects of dexmedetomidine. The aim of this study was to examine the association between dexmedetomidine and total perioperative opioid consumption in children undergoing adenotonsillectomy. METHODS: This was a retrospective cohort study of the children undergoing adenotonsillectomy surgery at Texas Children's Hospital between November 2017 and October 2018. Intraoperative dexmedetomidine was the exposure of interest. The primary outcome was total perioperative opioid consumption calculated as oral morphine equivalents (OME). Secondary outcomes of interest included opioid consumption and pain scores based on presence and absence of obstructive sleep apnea (OSA) and postanesthesia care unit (PACU) duration. We used multivariable linear regression to estimate the association of dexmedetomidine on the outcomes. RESULTS: A total of 941 patients met inclusion criteria, 697 (74.1%) received intraoperative dexmedetomidine. For every 0.1 µg/kg increase in intraoperative dexmedetomidine, the total perioperative OME (mg/kg) decreases by 0.021 mg/kg (95% CI, -0.027 to -0.015; P < .001). Pain scores did not significantly vary by OSA status. PACU duration increased by 1.14 minutes (95% CI, 0.30-1.99; P = .008) for each 0.1 µg/kg of intraoperative dexmedetomidine. CONCLUSIONS: Dexmedetomidine is associated with an overall perioperative opioid-sparing effect in children undergoing adenotonsillectomy and a small but statistically significant increase in PACU duration. Additionally, children with OSA did not have reduced perioperative opioid consumption.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Adler AC, Daszkowski A, Tan JC, et al. The Association of Dexmedetomidine on Perioperative Opioid Consumption in Children Undergoing Adenotonsillectomy With and Without Obstructive Sleep Apnea. Anesth Analg. 2021. PMID: 33591119. doi:10.1213/ANE.0000000000005410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。